US-Listed In Vitro & In Vivo Diagnostic Substances — Revenue Percentiles, FY 2024

Population: 17 US-listed companies (SIC 2835), fiscal year 2024; fiscal year ends 2024-12-29 to 2025-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile	$754.1k
25th percentile	$3.6M
Median	$9.2M
75th percentile	$837.6M
90th percentile	$2.0B
Mean	$594.4M
Minimum	$0
Maximum	$3.9B

Methodology & sources
Revenue as filed, one fiscal year per company; percentiles computed in the database via percentile_cont, never by a model. Fiscal year 2024 = fiscal years ending 2024-06-01 to 2025-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-02.

Evidence samples

Latest Revenue percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/revenue/2024